Nano-enabled nasal spray for osteoporosis

Nasal-spray445x124
17 Feb 2012 12:33:29.247

PA 54/12

The University of Nottingham spin-out company, Critical Pharmaceuticals, has announced a £545,000 collaboration with the University to develop a nano-enabled intranasal formulation of teriparatide for the treatment of osteoporosis.

Osteoporosis affects an estimated 75 million people in Europe, US and Japan with more than 180,000 patients suffer fragility fractures in the UK alone each year, at a cost of around £2 billion to the NHS.

Teriparatide, an excellent recent addition to the range of drugs used for the treatment of osteoporosis, but it currently needs to be injected every day. The consortium will exploit a recent discovery in nanotechnology to develop a nasal spray formulation of teriparatide that is easy to administer by patients and provides optimal drug plasma levels to enhance efficacy. 

Click here for full story

Story credits

More information is available from Dr Gareth King, CEO, Critical Pharmaceuticals, on +44 (0)115 882 0100, gareth.king@criticalpharmaceuticals.com
  Lindsay Brooke

Lindsay Brooke - Media Relations Manager

Email: lindsay.brooke@nottingham.ac.uk Phone: +44 (0)115 951 5751 Location: University Park

Additional resources

No additional resources for this article

Related articles

No related articles

Media Relations - External Relations

The University of Nottingham
YANG Fujia Building
Jubilee Campus
Wollaton Road
Nottingham, NG8 1BB

telephone: +44 (0) 115 951 5798
email: pressoffice@nottingham.ac.uk